Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05286593 · ClinicalTrials.gov registry record · Phase 4
3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
A Phase 4 study, sponsored by Ochsner Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
NCT05286593 is a Phase 4 study that has completed, run by Ochsner Health System. The registered enrollment target is 98 participants.
The verdict
NCT05286593, a Phase 4 study, has completed, sponsored by Ochsner Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
Study Summary
The investigators seek to test bolus infusions (50ml/min) vs. slow infusions (20 ml/min) of Rb-82 on metrics of coronary blood flow assessed on a modern 3D PET/CT.
Interventions
- DRUG Slow Infusion of Rubidium-82
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2021-12-28 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05286593
The ClinicalTrials.gov registry entry for NCT05286593 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ochsner Health System, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Slow Infusion of Rubidium-82 is the first listed.
NCT05286593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05286593 about?
NCT05286593 is a clinical study titled "3D PET Myocardial Blood Flow and Rb82 Infusion Profiles". The investigators seek to test bolus infusions (50ml/min) vs. slow infusions (20 ml/min) of Rb-82 on metrics of coronary blood flow assessed on a modern 3D PET/CT.
What is the current status of trial NCT05286593?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2021-12-28. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT05286593?
The interventions under investigation include: Slow Infusion of Rubidium-82 (DRUG).
Who is sponsoring clinical trial NCT05286593?
This trial is sponsored by Ochsner Health System, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.